Co-Diagnostics, Inc. (CODX)
The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of Co-Diagnostics, Inc. (CODX) who purchased shares between May 12, 2022 and August 11, 2022.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:
(i) demand for the Company’s Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants’ positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until October 17, 2022 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
Co-Diagnostics, Inc. Class Action Lawsuit
Co-Diagnostics, Inc. Lawsuit
CODX Class Action Lawsuit
Co-Diagnostics, Inc. (CODX) Class Action Lawsuit